Acorda Therapeutics, Inc. today announced data analyses show

Dalfampridine, or Ampyra, is a potassium channel blocker that is shown to improve visual function, motor skills and relieve fatigue in MS patients.

Acorda Therapeutics, Inc. today announced data analyses show

Postby MSUK » Tue Apr 12, 2011 7:31 am

Image

Acorda Therapeutics, Inc. today announced data analyses showing that people with multiple sclerosis (MS) who responded to Ampyra™ (dalfampridine) Extended Release Tablets, 10 mg had comparable improvements in their walking regardless of baseline walking speed or overall level of MS-related disability1.

In addition, Ampyra responders, regardless of baseline disability, showed clinically meaningful improvement on the 12-Item MS Walking Scale (MSWS-12), a patient-based questionnaire that measures the impact of MS on the patient's reported ability to perform daily activities related to walking. These and other post hoc analyses of Ampyra clinical trial and extension study data will be presented at the 63rd American Academy of Neurology (AAN) Annual Meeting being held April 9-16 in Honolulu, Hawaii.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1980
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Ampyra

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users